Free Trial
NASDAQ:OSRH

OSR Q1 2025 Earnings Report

OSR logo
$0.42 +0.01 (+3.42%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$0.41 -0.01 (-1.59%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR EPS Results

Actual EPS
-$1.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$0.76 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

OSR (NASDAQ:OSRH) Stock Price Up 3.4% - Still a Buy?
OSR Holdings Secures VXM01 Rights in Asset Deal
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile